A Phase 2B prospective, blinded, randomized, placebo controlled, international multicenter study to assess restoration of coronary artery blood flow and resolution of ST segment deviation after a single subcutaneous injection of RUC-4 in subjects with ST-elevation myocardial infarction presenting in the ambulance (pre-hospital setting)
Introduction
RUC-4 (zalunfiban) is an investigational drug. It is a novel, promising and fast acting (5-15 minutes) GPIIbIIIa inhibitor with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. For patients with ST-elevation myocardial infarction (STEMI) early treatment with RUC-4 could be beneficial by improving initial patency of the infarct related vessel and by minimizing thrombotic occlusions, thus improving both coronary artery and myocardial microvascular blood flow, possibly resulting in a decrease in infarct size and a reduction in complications of STEMI.
The CELEBRATE Trial is a phase 2B trial to assess restoration of coronary artery blood flow and resolution of ST segment deviation after a single subcutaneous injection of the fast-acting αIIbβ3 receptor antagonist RUC-4 in patients with STEMI presenting in the ambulance.
Sites and inclusion
This multi-center study will be conducted at up to 15 clinical sites (hospitals/ambulance services) in the Netherlands and Czech Republic. In the Celebrate trial, a total of 1668 subjects will be enrolled within two years, with a 12-month follow‑up period.
The first patient was included in the Isala hospital/Ambulance IJsselland, Zwolle, the Netherlands on April 24, 2021.
Sponsor
CeleCor Therapeutics Inc. is the study sponsor.
Clinical investigators
Coordinating Principal Investigator:
Prof. A.W.J. Van ‘t Hof, MD PhD (Interventional cardiologist, Head interventional cardiology, MUMC+, Maastricht)
National Principal investigator for the Netherlands:
Prof. J.M. ten Berg, MD PhD (Interventional cardiologist St. Antonius hospital, Nieuwegein, and professor antithrombotic therapy in cardiac interventions, MUMC+, Maastricht)
National Principal Investigator for the Czech Republic:
Prof. P. Kala, MD PhD (Interventional cardiologist, Deputy Executive Director, head of cathlab at University Hospital Brno)
Clinical study information
